Shopping Cart 0
Cart Subtotal
AED 0

Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Madrigal Pharmaceuticals Inc (MDGL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor beta, (THR-beta), agonist that can potentially be used for treating several disease with high unmet medical need. The company is developing MGL-3196 for non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has similar thyroid receptor selectivity to MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.

Madrigal Pharmaceuticals Inc Key Recent Developments

Jul 02,2019: Madrigal Pharmaceuticals announces appointment of Jim Daly to board of directors

May 08,2019: Madrigal Pharmaceuticals reports 2019 first quarter financial results and highlights

Feb 27,2019: Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Nov 06,2018: Madrigal Pharmaceuticals reports 2018 third quarter

Aug 07,2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Madrigal Pharmaceuticals Inc-Key Facts

Madrigal Pharmaceuticals Inc-Key Employees

Madrigal Pharmaceuticals Inc-Key Employee Biographies

Madrigal Pharmaceuticals Inc-Major Products and Services

Madrigal Pharmaceuticals Inc-History

Madrigal Pharmaceuticals Inc-Company Statement

Madrigal Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Madrigal Pharmaceuticals Inc-Business Description

Madrigal Pharmaceuticals Inc-Corporate Strategy

Madrigal Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Madrigal Pharmaceuticals Inc-Strengths

Madrigal Pharmaceuticals Inc-Weaknesses

Madrigal Pharmaceuticals Inc-Opportunities

Madrigal Pharmaceuticals Inc-Threats

Madrigal Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 02, 2019: Madrigal Pharmaceuticals announces appointment of Jim Daly to board of directors

May 08, 2019: Madrigal Pharmaceuticals reports 2019 first quarter financial results and highlights

Feb 27, 2019: Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Nov 06, 2018: Madrigal Pharmaceuticals reports 2018 third quarter

Aug 07, 2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements

May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements

Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Madrigal Pharmaceuticals Inc, Performance Chart (2014-2018)

Madrigal Pharmaceuticals Inc, Ratio Charts

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Madrigal Pharmaceuticals Inc, Key Facts

Madrigal Pharmaceuticals Inc, Key Employees

Madrigal Pharmaceuticals Inc, Key Employee Biographies

Madrigal Pharmaceuticals Inc, Major Products and Services

Madrigal Pharmaceuticals Inc, History

Madrigal Pharmaceuticals Inc, Subsidiaries

Madrigal Pharmaceuticals Inc, Key Competitors

Madrigal Pharmaceuticals Inc, Ratios based on current share price

Madrigal Pharmaceuticals Inc, Annual Ratios

Madrigal Pharmaceuticals Inc, Annual Ratios (Cont...1)

Madrigal Pharmaceuticals Inc, Interim Ratios

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Madrigal Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novo Nordisk AS

Novartis AG

Intercept Pharmaceuticals Inc

Immuron Ltd

Gilead Sciences Inc

Gemphire Therapeutics Inc

Galectin Therapeutics Inc

Esperion Therapeutics Inc

Boehringer Ingelheim International GmbH

Amgen Inc

Allergan Plc

Company Profile

Company Profile Title

Madrigal Pharmaceuticals Inc (MDGL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor beta, (THR-beta), agonist that can potentially be used for treating several disease with high unmet medical need. The company is developing MGL-3196 for non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has similar thyroid receptor selectivity to MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.

Madrigal Pharmaceuticals Inc Key Recent Developments

Jul 02,2019: Madrigal Pharmaceuticals announces appointment of Jim Daly to board of directors

May 08,2019: Madrigal Pharmaceuticals reports 2019 first quarter financial results and highlights

Feb 27,2019: Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Nov 06,2018: Madrigal Pharmaceuticals reports 2018 third quarter

Aug 07,2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Madrigal Pharmaceuticals Inc-Key Facts

Madrigal Pharmaceuticals Inc-Key Employees

Madrigal Pharmaceuticals Inc-Key Employee Biographies

Madrigal Pharmaceuticals Inc-Major Products and Services

Madrigal Pharmaceuticals Inc-History

Madrigal Pharmaceuticals Inc-Company Statement

Madrigal Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Madrigal Pharmaceuticals Inc-Business Description

Madrigal Pharmaceuticals Inc-Corporate Strategy

Madrigal Pharmaceuticals Inc-SWOT Analysis

SWOT Analysis-Overview

Madrigal Pharmaceuticals Inc-Strengths

Madrigal Pharmaceuticals Inc-Weaknesses

Madrigal Pharmaceuticals Inc-Opportunities

Madrigal Pharmaceuticals Inc-Threats

Madrigal Pharmaceuticals Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 02, 2019: Madrigal Pharmaceuticals announces appointment of Jim Daly to board of directors

May 08, 2019: Madrigal Pharmaceuticals reports 2019 first quarter financial results and highlights

Feb 27, 2019: Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Nov 06, 2018: Madrigal Pharmaceuticals reports 2018 third quarter

Aug 07, 2018: Madrigal Pharmaceuticals reports 2018 second quarter financial results and reviews key clinical achievements

May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements

Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Madrigal Pharmaceuticals Inc, Performance Chart (2014-2018)

Madrigal Pharmaceuticals Inc, Ratio Charts

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Madrigal Pharmaceuticals Inc, Key Facts

Madrigal Pharmaceuticals Inc, Key Employees

Madrigal Pharmaceuticals Inc, Key Employee Biographies

Madrigal Pharmaceuticals Inc, Major Products and Services

Madrigal Pharmaceuticals Inc, History

Madrigal Pharmaceuticals Inc, Subsidiaries

Madrigal Pharmaceuticals Inc, Key Competitors

Madrigal Pharmaceuticals Inc, Ratios based on current share price

Madrigal Pharmaceuticals Inc, Annual Ratios

Madrigal Pharmaceuticals Inc, Annual Ratios (Cont...1)

Madrigal Pharmaceuticals Inc, Interim Ratios

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Madrigal Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Madrigal Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Novo Nordisk AS

Novartis AG

Intercept Pharmaceuticals Inc

Immuron Ltd

Gilead Sciences Inc

Gemphire Therapeutics Inc

Galectin Therapeutics Inc

Esperion Therapeutics Inc

Boehringer Ingelheim International GmbH

Amgen Inc

Allergan Plc